Survival Analysis of Immunotherapy Effects on Relapse Rate in Pediatric and Adult Autoimmune Encephalitis
- 28 November 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 101 (22) , E2300-E2313
Abstract
Background and Objectives: Prior observational studies for autoimmune encephalitis (AE) have mostly focused on outcomes following acute immunotherapies with better outcomes associated with earlier immunotherapy use. However, the impact of long-term immunotherapy and its association with clinical relapse is not well known. Methods: We conducted a retrospective study of consecutive patients meeting published clinical criteria for AE evaluated at UC San Diego and Rady Children’s Hospital from January 2007 to November 2021. Survival analysis and Cox multivariable regression models were employed to evaluate relapse risk using rituximab exposure as a time-dependent variable. Pooled and age-stratified analyses were performed. Results: A total of 204 pediatric and 380 adult participants were screened of which 30 pediatric and 75 adult participants were included. The most common antibody subtype in both cohorts was anti-NMDA receptor (76% in pediatric, 34% in adult). Relapses occurred in 31% of pediatric antibody-positive, 40% of adult antibody-positive, and 20% of adult antibody-negative cases. Times to first relapse (TTFR) were 10.6 ± 7.4 months (pediatric antibody-positive), 13.1 ± 24.5 (adult antibody-positive) and 6.9 ± 3.8 months (adult antibody-negative). Rituximab was the most common second-line immunotherapy used. Combining pediatric and adult data, rituximab use was associated with a 71% lower hazard for time to first relapse (HR 0.29, 95% CI 0.09 – 0.85) and 51% lower hazard for recurring relapses (HR 0.49, 95% CI 0.9 – 1.26). The HR for TTFR with rituximab use in children was 0.30 (95% CI 0.05 – 1.69), 0.29 (95% CI 0.07 – 1.29) in adults, 0.32 in non-NMDA antibody-positive encephalitis (95% CI 0.07 – 1.39, and 0.42 (95% CI 0.07 – 2.67) for anti-NMDAR. Discussion: Relapses are common in pediatric and adult patients with AE, although less frequently in anti-NMDARE. Employing a rigorous survival model, we demonstrate a substantial benefit of rituximab use for reducing relapse rates in AE, especially for the adult population. Classification of Evidence: This study provides Class IV evidence that rituximab is associated with a lower hazard to relapse in patients with autoimmune encephalitis.Keywords
This publication has 25 references indexed in Scilit:
- Rituximab treatment for autoimmune limbic encephalitis in an institutional cohortNeurology, 2016
- A clinical approach to diagnosis of autoimmune encephalitisThe Lancet Neurology, 2016
- Antibody-Mediated Autoimmune Encephalopathies and ImmunotherapiesNeurotherapeutics, 2016
- Immune therapy in autoimmune encephalitis: a systematic reviewExpert Review of Neurotherapeutics, 2015
- Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort studyThe Lancet Neurology, 2013
- The Frequency of Autoimmune N-Methyl-D-Aspartate Receptor Encephalitis Surpasses That of Individual Viral Etiologies in Young Individuals Enrolled in the California Encephalitis ProjectClinical Infectious Diseases, 2012
- Analysis of relapses in anti-NMDAR encephalitisNeurology, 2011
- Anti–N‐methyl‐D‐aspartate receptor (NMDAR) encephalitis in children and adolescentsAnnals of Neurology, 2009
- Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trialAnnals of Neurology, 2008
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple SclerosisNew England Journal of Medicine, 2008